Summit stock crashes as Akeso shares bispecific's first overall survival data in Keytruda head-to-head trial
Akeso has shared for the first time overall survival data from a high-profile Keytruda head-to-head trial for its PD-1xVEGF bispecific ivonescimab—and investors in its partner Summit Therapeutics aren’t taking the result too well.
Akeso has shared for the first time overall survival data from a high-profile Keytruda head-to-head trial for its PD-1xVEGF bispecific ivonescimab—and investors in its partner Summit Therapeutics aren’t taking the result too well.
